Group 1 - The core viewpoint of the article highlights the strategic initiatives of Erkang Pharmaceutical to enhance its market position in the raw material sector, particularly in customized services and product quality improvement [1] - In 2024, the company aims to integrate internal and external resources within the raw material sector and optimize its organizational structure to boost product quality and performance [1] - The sales volume of modified starch and starch capsule series products is expected to grow, achieving a revenue of 56.406 million yuan, representing a year-on-year increase of 81.89% [1] Group 2 - The sales revenue of injection auxiliary materials increased by 13.28% year-on-year, while the sales revenue of external preparation auxiliary materials grew by 29.87% [1] - The number of new customers developed for niacinamide remains steadily increasing, indicating a positive trend in customer acquisition [1]
[路演]尔康制药:2024年努力提高细分注射用辅料领域的市场占有率